DLX2蛋白在胃癌的表达与临床意义

发布时间：2018-09-06 10:04

【摘要】：背景胃癌是最常见的恶性消化道肿瘤之一,发病率及死亡率均位于前列。对于很多国家,尤其是发展中国家而言是十分重要的公共卫生问题。我国是胃癌高发地区之一。据统计,我国胃癌发病占全世界42%左右,农村发病率超过城市。然而,胃癌的病因及发病机制仍不明确。因此,研究其发生、发展、浸润、转移相关的分子调控机制对了解疾病、促进治疗具有重要意义。同源盒转录因子基因2(DLX2, distal-less homeobox2)是DLX基因家族中的一员。已有大量研究证实DLX2对于胚胎发育有及其重要的作用,但关于它在肿瘤中的作用在近些年才被提出。已有研究证明在血液系统肿瘤、胶质瘤、乳腺癌等恶性肿瘤中均有DLX2异常表达。在胃癌中仅有一项研究,认为DLX2的表达与肿瘤分期有关。本研究运用大样本量的组织芯片及免疫组织化学技术对胃癌组织中DLX2蛋白的表达进行测定,并结合临床病理资料探索其临床意义,为未来进一步的研究提供方向。目的检测DLX2蛋白在胃癌组织芯片中的表达水平并分析其临床意义。方法收集浙江大学附属邵逸夫医院肿瘤外科1997年至2011年胃癌术后组织标本472例。同时整理相关临床信息及随访资料。参照文献中的制作方法,将组织蜡块制成组织芯片。然后对芯片进行免疫组化染色,请两位有经验的病理科医师读片,观察DLX2蛋白的表达情况。最终我们汇总得到262例有完整信息的病例。统计分析这些病例胃癌组织中DLX2蛋白的表达与临床意义。结果 1.列联分析提示DLX2蛋白的表达与Her-2蛋白表达有明显的相关性,Her-2阴性组中DLX2的表达较阳性组高。(p=0.004)。 2. Kaplan Meier生存分析及COX比例风险模型提示DLX2对胃癌患者生存无显著性影响,但DLX2高表达患者的中位生存期较低表达患者降低。结论 DLX2蛋白在胃癌组织中有表达,且与Her-2蛋白表达明显相关,但对生存无显著影响。
[Abstract]:Background gastric cancer is one of the most common malignant digestive tract tumors, morbidity and mortality are in the forefront. It is a very important public health problem for many countries, especially developing countries. China is one of the regions with high incidence of gastric cancer. According to statistics, the incidence of gastric cancer in China accounts for about 42% of the world. However, the etiology and pathogenesis of gastric cancer are still unclear. Therefore, it is important to study the molecular regulatory mechanisms related to its occurrence, development, infiltration and metastasis in order to understand disease and promote treatment. Homologous cassette transcription factor 2 (DLX2, distal-less homeobox2) is a member of DLX gene family. A large number of studies have confirmed that DLX2 plays an important role in embryonic development, but its role in tumor has only been proposed in recent years. Abnormal expression of DLX2 has been demonstrated in hematological tumors, gliomas, breast cancer and other malignancies. In only one study of gastric cancer, the expression of DLX2 was associated with tumor staging. In this study, the expression of DLX2 protein in gastric cancer tissues was determined by tissue microarray and immunohistochemical technique, and its clinical significance was explored in combination with clinicopathological data, which provided a direction for further research in the future. Objective to detect the expression of DLX2 protein in gastric cancer tissue microarray and analyze its clinical significance. Methods 472 specimens of gastric cancer were collected from 1997 to 2011 in Shaw Hospital of Zhejiang University. At the same time, the clinical information and follow-up data were collected. The tissue wax block was made into tissue chip according to the method in the literature. Then the microarray was stained by immunohistochemistry and two experienced pathologists were asked to read the film and observe the expression of DLX2 protein. Finally, we gathered 262 cases with complete information. The expression and clinical significance of DLX2 protein in gastric cancer tissues were analyzed statistically. Result 1. The DLX2 expression in Her-2 negative group was significantly higher than that in positive group (p0. 004). 2. Kaplan Meier survival analysis and COX proportional risk model suggested that DLX2 had no significant effect on the survival of gastric cancer patients, but the median survival time of patients with high DLX2 expression was lower than that of patients with low DLX2 expression. Conclusion the expression of DLX2 protein in gastric cancer tissues was significantly related to the expression of Her-2 protein, but had no significant effect on survival.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R735.2

【参考文献】